SPRO Spero Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1701108 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY2.5%
TTM net income YoY32.7%
TTM EPS YoY36.7%
Revenue 3-yr CAGR-18.8%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-67.3%
Net margin-71.0%
FCF margin—
EBITDA margin—
Returns
ROE-216.4%
ROA-35.9%
ROIC (approx.)—
Asset turnover0.51x
Leverage & solvency
Liabilities / assets99.3%
Debt / equity0.00x
Current ratio1.92x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.37x
Accruals ratio13.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $0 | $258,000 | $41.30M | $5.44M | $14.19M | $5.87M | $15.04M |
| R&D expense | $3.20M | $3.43M | $2.91M | $5.59M | $8.60M | $10.67M | $13.61M | $28.84M |
| SG&A expense | $3.72M | $6.49M | $4.89M | $4.30M | $4.17M | $5.88M | $6.82M | $7.06M |
| Operating income | -$41.91M | -$9.93M | -$7.54M | $31.41M | -$7.92M | -$2.44M | -$14.73M | -$21.73M |
| Income tax | — | — | — | $261,000 | $0 | — | — | $290,000 |
| Net income | -$44.28M | -$9.55M | -$7.20M | $31.52M | -$7.38M | -$1.70M | -$13.87M | -$20.89M |
| EBITDA | — | — | — | $31.41M | -$7.92M | — | — | -$21.73M |
| EPS (basic) | -0.76 | -0.16 | -0.13 | — | -0.13 | -0.03 | -0.25 | — |
| EPS (diluted) | -0.76 | -0.16 | -0.13 | — | -0.13 | -0.03 | -0.25 | — |
| Weighted avg. shares (diluted) | 58.23M | 57.97M | 57.28M | — | 56.28M | 56.03M | 55.38M | — |
| Banking | ||||||||
| Net interest income | $2.37M | — | — | — | -$532,000 | — | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | $107.93M | $50.77M | $56.13M | $40.27M | $48.62M | $31.19M | $48.89M | $52.89M |
| Current assets | $109.23M | $51.58M | $57.61M | $67.29M | $52.32M | $59.40M | $74.71M | $107.28M |
| PP&E, net | — | — | — | — | — | — | — | $0 |
| Total assets | $110.03M | $52.77M | $59.02M | $68.92M | $54.17M | $62.12M | $77.71M | $110.54M |
| Current liabilities | $56.96M | $8.43M | $5.49M | $8.87M | $13.65M | $14.95M | $29.16M | $49.07M |
| Total liabilities | $109.25M | $8.56M | $6.09M | $9.90M | $27.68M | $29.29M | $43.90M | $64.42M |
| Shareholders' equity | $781,000 | $44.20M | $52.93M | $59.02M | $26.49M | $32.83M | $33.81M | $46.12M |
| Shares outstanding | 58.24M | 58.15M | 57.89M | 56.41M | 56.31M | 56.19M | 55.90M | 54.59M |
| Cash flow statement | ||||||||
| Operating cash flow | -$42.61M | -$5.36M | $15.86M | -$8.35M | $17.42M | -$17.69M | -$4.00M | -$23.40M |
| Financing cash flow | — | — | — | — | — | — | — | $0 |
| Depreciation & amortization | — | — | — | $0 | $0 | — | — | $0 |
| Stock-based compensation | $855,000 | $822,000 | $1.11M | $1.01M | $1.05M | $714,000 | $1.56M | $1.50M |
Free plan shows the latest 8 periods; Pro shows all 43 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.